MARKET

RENXF

RENXF

Renalytix Plc
OTCMQB
0.088
NaN%
Closed 09:30 09/10 EDT
OPEN
--
PREV CLOSE
0.088
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.163
52 WEEK LOW
0.023
MARKET CAP
38.33M
P/E (TTM)
-1.6705
1D
5D
1M
3M
1Y
5Y
1D
Renalytix Seeks Shareholder Approval for Fundraising to Scale Kidney Diagnostics
TipRanks · 1d ago
Renalytix Raises £10.5 Million and Prepares Second Tranche Share Admission on AIM
TipRanks · 2d ago
Renalytix Opens £1 Million WRAP Retail Offer Alongside £10.1 Million Fundraise
TipRanks · 09/03 06:17
Renalytix Raises £10.1m and Wipes Out HCM Debt to Fund U.S. Kidney Test Expansion
TipRanks · 09/03 06:11
Renalytix raises £9.5m to fund U.S. kidney-test rollout and cuts debt via bond conversion
TipRanks · 09/01 06:28
Renalytix partners with Quest to expand U.S. rollout of kidneyintelX.dkd test
TipRanks · 09/01 06:13
Renalytix Discloses Director’s Link to Trellus Administration as KidneyIntelX Rollout Advances
TipRanks · 08/24 13:42
Renalytix’s KidneyIntelX Study Update: What Ongoing Real-World Data Means for RENXF Investors
TipRanks · 08/13 16:31
More
About RENXF
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Webull offers Renalytix PLC stock information, including OTCMQB: RENXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RENXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RENXF stock methods without spending real money on the virtual paper trading platform.